Le Nghiem Quan, Vo Trung Quang, Doan Tuan Duc
Department of Pharmacy Industry, University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam.
Department of Economic and Administrative Pharmacy, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam.
J Pak Med Assoc. 2019 Jun;69(Suppl 2)(6):S34-S40.
Colorectal cancer (CRC) is the third most common, and the second deadliest, cancer documented in recent years, and numerous studies have addressed this issue. Nevertheless, little attention has been given to the CRC burden in Vietnam. Our study aims to analyze variations in cost for CRC treatments using the cost of illness (COI) method.
Utilizing medical records spanning from 2014 to 2017 supplied by a primary healthcare facility in Ho Chi Minh City, a population of 9,126 patients, diagnosed with and treated for CRC, was analyzed in terms of demographic detail and individual treatment cost.
Among the 9,126 patients hospitalized with CRC, 3,699 patients were between the ages of 50 and 65. Colon cancer accounted for 56.4% and 60.4% of the total patients in Inpatient Department (IPD) and Outpatient Department (OPD). The total direct medical cost was calculated to be over ten million USD for IPD patients and over three million USD for OPD patients over a four year span of data. The per-patient cost was $2,741.00 (IPD) and $588.80 (OPD), with chemotherapy drugs being 53% (IPD) and 73% (OPD) of the overall treatment cost. Patients going through both treatment regimens incurred a mean cost of $4,271.20 (IPD) and $1,779.80 (OPD).
There is a similarity in the costs of CRC treatment in developing countries in Asia. Despite many limitations, we are certain this study will be useful for future studies regarding the CRC burden in Asia in general, as well as in developing countries like Vietnam.
结直肠癌(CRC)是近年来记录在案的第三大常见癌症,也是第二大致命癌症,众多研究都探讨过这一问题。然而,越南的结直肠癌负担却很少受到关注。我们的研究旨在使用疾病成本(COI)方法分析结直肠癌治疗成本的差异。
利用胡志明市一家基层医疗机构提供的2014年至2017年的病历,对9126名被诊断患有结直肠癌并接受治疗的患者群体进行了人口统计学细节和个人治疗成本分析。
在9126名因结直肠癌住院的患者中,3699名患者年龄在50至65岁之间。结肠癌占住院部(IPD)和门诊部(OPD)总患者数的56.4%和60.4%。在四年的数据跨度内,IPD患者的直接医疗总成本计算超过1000万美元,OPD患者超过300万美元。每位患者的成本为2741.00美元(IPD)和588.80美元(OPD),化疗药物分别占总治疗成本的53%(IPD)和73%(OPD)。接受两种治疗方案的患者平均成本为4271.20美元(IPD)和1779.80美元(OPD)。
亚洲发展中国家的结直肠癌治疗成本存在相似性。尽管存在许多局限性,但我们确信这项研究将对未来关于亚洲总体结直肠癌负担以及越南等发展中国家的研究有用。